Search Results
43 Results Found for “cirrhosis”
At EASL 2026, Lung-Yi Loey Mak discusses evolving hepatitis B management in young patients, including early treatment strategies, perinatal prevention, global practice variations and emerging approaches to cancer risk prediction.
The global prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) has increased over the past three decades and is estimated to be 30% as of 2022.1Â As an indication of disease burden, MASLD-related liver transplantation has already surpassed many other aetiologies as ...
The American Association for the Study of Liver Diseases (AASLD) has released a significant update to its practice guidance on metabolic dysfunction–associated steatotic liver disease (MASLD), formally incorporating semaglutide as a recommended therapeutic option for adults with MASH and F2–F3 fibrosis. This expansion comes following the August 2025 accelerated FDA approval of semaglutide for MASH with moderate-to-advanced fibrosis, following positive interim Phase 3 findings.
The AASLD 2025 Liver Meeting® (7–11 November, Washington, D.C., USA) delivered a breadth of early- and late-phase data across metabolic liver disease, cholestatic conditions, liver failure, and rare liver diseases. This year’s findings reflected a rapidly evolving therapeutic landscape, with meaningful progress in mechanistic understanding, emerging signals of disease modification, and increasing momentum toward more precise, combination-oriented strategies across multiple liver conditions.
Fatty liver is the largest liver disease globally and has become a leading cause of liver cirrhosis and end-stage liver disease. Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic steatohepatitis (NASH), affects about one-third of the adult population ...
Dr Thinzar Min discusses how the Enhanced Liver Fibrosis (ELF) test could help detect liver fibrosis and assess cardiovascular risk in people with type 2 diabetes.
This Q&A with Dr Paul Brennan offers a practical guide to the diagnosis and management of metabolic dysfunction-associated steatohepatitis (MASH). Covering key risk factors, non-invasive diagnostic tools, lifestyle strategies, and emerging therapies, it provides clinicians with clear approaches to early detection and comprehensive patient care.
Hyponatraemia is primarily a disorder of water balance or distribution, characterized by serum sodium (Nas) levels less than 135 mmol/L.1 Hyponatraemia is the most common electrolyte disorder among elderly patients and is associated with increased mortality rates and longer hospital ...
Article Highlights This study aims to find an effective and affordable biomarker panel for early non-alcoholic fatty liver disease (NAFLD) detection in Indian women with morbid obesity, given the rising prevalence of NAFLD and limited accessibility of ultrasound sonography (USG) ...
Article highlights There is growing clinical importance attributed to the development of metabolic dysfunction-associated steatotic liver disease in people with type 2 diabetes (T2D). Numerous international groups now advocate screening for advanced fibrosis in people with risk factors, such as ...
In this recent video interview hosted by Sarah Manes, Liver Cancers Program Director at the Global Liver Institute (GLI), medical experts from the USA, Cameroon and Mexico came together to address the significant health disparities in rural communities. The discussion ...
Hepatic steatosis is the liver manifestation of metabolic syndrome and a common cause of chronic liver disease. Nonalcoholic fatty liver disease (NAFLD) diagnosis relies on the presence of hepatic steatosis, defined as >5% fat accumulation in the liver, as observed ...
Type 2 diabetes (T2D) continues to pose an ever-greater global health challenge, with 1.31 billion individuals predicted to be living with diabetes globally by 2050; the majority of whom will have T2D.1Â Closely linked to T2D is metabolic dysfunction-associated steatotic ...
There has been an exponential increase in the global prevalence of obesity over the past few decades because of adverse lifestyle choices, such as physical inactivity and overconsumption of macronutrients. The obesity pandemic has contributed to more than 50 different disorders ...
Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of fatty liver diseases, including non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH).1 NAFLD is associated with metabolic disorders, including obesity, hypertension, dyslipidaemia, type 2 diabetes mellitus (T2DM), hypothyroidism and metabolic syndrome.2 ...
Welcome to the latest edition of touchREVIEWS in Endocrinology, which includes a broad range of articles selected for their evaluation of current practices and research that directly affect endocrinologists as well as being of interest to the wider biomedical community. ...
Non-alcoholic fatty liver disease (NAFLD), which impacts an estimated 25% of the world’s adult population,1–3 is the principal cause of chronic liver disease globally. NAFLD as a whole represents a pathological spectrum of liver injury, spanning from simple steatosis to ...
Nonalcoholic steatohepatitis (NASH) has a relatively short history as a recognized health condition. The terminology for NASH and its precursor nonalcoholic fatty liver disease (NAFLD) date back to only the 1980s1. As a young disease, the stakeholders from throughout the ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
